Dry Powder Inhaler (DPI) Particle Size Testing: Aerodynamic Size Analysis, Methods, and Standards

Dry powder inhaler (DPI) particle size testing determines whether an inhaled pharmaceutical product can deliver drug particles to the targeted regions of the respiratory tract. Using compendial cascade impaction and laser diffraction techniques, accredited third-party laboratories and pharmaceutical manufacturers measure aerodynamic particle size distribution, mass median aerodynamic diameter (MMAD), geometric standard deviation (GSD), and fine particle fraction in accordance with USP, Ph. Eur., ChP, and ISO standards. This article outlines the technical background, sample types, testing items, analytical methods, applications, and frequently asked questions related to DPI particle size characterization.

Technical Overview

Dry powder inhalers (DPIs) deliver micronized drug powder, with or without a carrier such as lactose, to the lungs for local or systemic therapy. Because deposition in the respiratory tract is governed primarily by aerodynamic particle size, particle size testing is one of the most critical quality attributes and performance indicators for any DPI product. Particles larger than approximately 5 μm tend to deposit in the oropharynx by inertial impaction, while particles smaller than approximately 1 μm may be exhaled before depositing; the therapeutically effective range for most inhaled products is therefore considered to be 1–5 μm.

Aerodynamic diameter is defined as the diameter of a unit-density sphere that has the same settling velocity in air as the particle of interest. It combines the effects of geometric size, shape, and density, making it the most relevant size metric for inhalation products. DPI particle size characterization is typically performed along two complementary dimensions: primary (geometric) particle size of the powder measured by laser diffraction, and the aerodynamic particle size distribution (APSD) of the aerosolized dose measured by cascade impaction.

Testing is conducted in accordance with recognized pharmacopoeial and international standards, including USP General Chapter <601> (Aerosols, Nasal Sprays, Metered-Dose Inhalers, and Dry Powder Inhalers), USP General Chapter <429> (Light Diffraction Measurement of Particle Size), Ph. Eur. 2.9.18 (Preparations for Inhalation: Aerodynamic Assessment of Fine Particles), the Chinese Pharmacopoeia General Chapter 0111 for inhalation preparations, and ISO 13320 for laser diffraction particle size analysis.

• Aerodynamic particle size distribution (APSD) of the delivered aerosol
• Mass median aerodynamic diameter (MMAD) and geometric standard deviation (GSD)
• Fine particle dose (FPD) and fine particle fraction (FPF), typically defined as the mass below 5 μm
• Primary particle size distribution of the bulk powder (Dv10, Dv50, Dv90)
• Delivered dose and emitted dose characteristics of the finished product

Testing Samples

Finished DPI Products

Complete inhalation products submitted in their final device configuration, including single-dose capsule-based DPIs, multi-dose blister- or foil-strip-based systems, and multi-dose reservoir-based devices. Testing is performed on the assembled device together with its formulation to evaluate the size of the aerosol actually emitted at the patient interface under pharmacopoeial flow conditions.

Micronized Active Pharmaceutical Ingredients

Bulk drug substances intended for inhalation delivery, typically manufactured by jet milling, spray drying, or controlled crystallization. Primary particle size testing of the API confirms that the micronization process consistently produces particles within the respirable size range before formulation.

Carrier and Excipient Powders

Coarse and fine lactose grades, alternative carrier particles, force-control additives, and adhesive blends used in carrier-based DPI formulations. Size characterization of these components supports formulation development, blend uniformity evaluation, and deagglomeration performance studies.

Development Batches and Stability Samples

Clinical trial supplies, registration batches, scale-up batches, placebo formulations, and samples stored under ICH long-term and accelerated stability conditions. Ongoing particle size testing verifies that storage, humidity exposure, and device aging do not adversely affect aerosolization performance.

Testing Items

Depending on the stage of development and the purpose of the study, DPI particle size testing may encompass the following items:

• Aerodynamic particle size distribution of the emitted dose, stage by stage
• Mass median aerodynamic diameter (MMAD), typically expected within approximately 1–5 μm for lung deposition
• Geometric standard deviation (GSD), describing the breadth of the size distribution
• Fine particle dose (FPD) and fine particle fraction (FPF), commonly calculated for particles smaller than 5 μm, and extra-fine fractions below 1–3 μm where region-specific deposition is required
• Emitted dose, delivered dose uniformity across the labeled number of doses, and total recovered dose
• Mass balance verification, typically within 85–115% of label claim per regulatory guidance
• Primary geometric particle size distribution of bulk powders, reported as Dv10, Dv50, and Dv90
• Agglomerate content and deagglomeration efficiency of powder blends

Testing Methods

DPI particle size testing relies primarily on compendial cascade impaction for aerodynamic assessment, complemented by laser diffraction for primary particle size and by microscopy or other techniques for morphological characterization.

Aerodynamic Assessment by Cascade Impaction

Cascade impaction is the pharmacopoeial reference method for determining the aerodynamic particle size distribution of the dose emitted from a DPI. The inhaler is connected to a compendial induction port and a multi-stage impactor, and air is drawn through the system at a controlled flow rate. For DPIs, the test flow rate is selected to achieve a pressure drop of 4.0 kPa across the device, within the range of approximately 30–100 L/min, as specified in Ph. Eur. 2.9.18 and USP <601>. Commonly used compendial apparatus include:

• Next Generation Impactor (NGI, USP Apparatus G): seven stages plus a micro-orifice collector, with cutoff diameters spanning approximately 0.3–8 μm at 60 L/min; widely used for both DPI and MDI testing
• Andersen Cascade Impactor (ACI, USP Apparatus D): eight stages with nominal cutoffs from approximately 9.0 μm down to 0.4 μm at the standard 28.3 L/min flow rate
• Multi-Stage Liquid Impinger (MSLI, USP Apparatus F): liquid-stage collection that minimizes particle bounce and re-entrainment for certain formulations

After actuation of a defined number of doses, the drug deposited on the induction port, pre-separator, individual stages, and filter is recovered and quantified by a validated analytical method such as HPLC or UV spectrophotometry. MMAD and GSD are derived from the cumulative mass-weighted size distribution using log-probit analysis, and fine particle metrics are calculated from the mass collected on stages with cutoffs below 5 μm. Stage mensuration and impactor calibration are performed at regular intervals to ensure data integrity.

Laser Diffraction for Primary Particle Size

Laser diffraction performed in accordance with ISO 13320 and USP <429> measures the volume-equivalent geometric size distribution of bulk powders. Dry dispersion modules apply controlled air pressure to deagglomerate the powder before measurement, providing rapid determination of Dv10, Dv50, and Dv90. The technique is fast and highly reproducible but does not distinguish between drug and excipient, and it does not measure aerodynamic behavior; it is therefore used alongside, not instead of, cascade impaction.

Supporting Characterization Techniques

Scanning electron microscopy (SEM) and optical microscopy are used to evaluate particle morphology, surface texture, and agglomeration. Time-of-flight aerodynamic sizing instruments provide real-time aerodynamic measurements and are useful for research applications, although they are not compendial release methods. Delivered dose uniformity testing, performed with a dedicated sampling apparatus at the same 4 kPa flow condition, is typically conducted together with APSD testing to give a complete picture of dose delivery performance.

Applications

DPI particle size testing supports the entire product lifecycle, from early formulation research to commercial batch release, for originator products, generics, and combination products alike:

• Formulation development: optimizing micronization parameters, carrier blends, and drug-to-carrier ratios to maximize fine particle fraction
• Device development and selection: evaluating deagglomeration efficiency, flow-rate dependence, and device resistance across patient inspiratory profiles
• Generic development: generating in vitro equivalence data comparing test and reference products under identical impaction conditions
• Quality control and batch release: demonstrating compliance with product-specific APSD, delivered dose, and mass balance specifications
• Stability programs: monitoring particle growth, agglomeration, or moisture-induced performance changes under ICH storage conditions
• Regulatory submission: providing analytical data packages supporting investigational, registration, and post-approval filings
• Manufacturing troubleshooting: investigating deviations in blend uniformity, capsule or blister filling, and environmental control

FAQ

Why is the 1–5 μm aerodynamic size range so important for DPIs?

Aerodynamic diameter directly controls where particles deposit in the respiratory tract. Particles above about 5 μm are mainly captured by inertial impaction in the mouth and throat, while particles below about 1 μm often remain suspended and are exhaled. The 1–5 μm window therefore represents the size range most likely to reach the bronchial and pulmonary regions where inhaled therapy is intended to act.

What flow rate is used for DPI cascade impaction testing?

Unlike metered-dose inhalers, DPI performance depends on the patient's inspiratory flow. Pharmacopoeial methods therefore specify that the test flow rate be adjusted to generate a pressure drop of 4.0 kPa across the inhaler, normally constrained to approximately 30–100 L/min, and the flow must stabilize for a defined duration before and during actuation. The ACI is classically operated at 28.3 L/min, while the NGI is commonly run at 60 L/min for DPI testing.

What is the difference between the NGI and the ACI?

Both are compendial cascade impactors recognized in USP <601> and Ph. Eur. 2.9.18. The NGI offers fewer stages with higher collection surface area, easier and faster recovery, and excellent resolution in the fine particle range, making it the preferred modern instrument for many laboratories. The ACI has a long historical database and remains widely used, particularly for products with established ACI-based specifications.

Why measure both laser diffraction size and aerodynamic size?

Laser diffraction characterizes the geometric size of the bulk powder and is fast and reproducible, but it cannot predict aerodynamic behavior because it does not account for density, shape, or the deagglomeration that occurs inside the device. Cascade impaction measures the actual aerodynamic size of the emitted aerosol cloud and is the pharmacopoeial basis for fine particle dose and MMAD specifications. The two methods are complementary and are both expected in a complete DPI control strategy.

How is fine particle fraction calculated?

Fine particle fraction is the ratio of the fine particle dose, meaning the mass of drug collected on impactor stages with cutoff diameters below 5 μm, to a reference mass such as the delivered dose, the emitted dose, or the label claim. The exact denominator must be defined in the product specification, and consistent methodology is essential when comparing data across laboratories or between test and reference products.

Are there universal acceptance criteria for DPI particle size?

No. Acceptance criteria for MMAD, GSD, fine particle dose, delivered dose uniformity, and mass balance are product-specific and established during development based on clinical data and process capability. Regulatory guidance generally expects mass balance within 85–115% of label claim and impaction data of sufficient quality to support the proposed specification, with testing performed in accredited third-party laboratories or qualified GMP facilities using calibrated, compendial apparatus.